SCHEMBL396344

SCHEMBL396344

Cc1ccc(NC(=O)c2ccccc2)cc1NC(=O)Nc1ccc2c(c1)NC(=O)C2=Cc1c(C)c(C(=O)O)c(C)n1C(C(N)=O)N1CCCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FLT3 P36888 10/20 0.47
▸ FLT4 P35916 8/20 0.47
▸ KDR P35968 7/20 0.47
▸ KIT P10721 6/20 0.47
▸ IDH2 P48735 1/20 0.44
▸ AURKB Q96GD4 5/20 0.42
▸ NTRK1 P04629 4/20 0.41
▸ PDGFRB P09619 2/20 0.41
▸ CSF1R P07333 2/20 0.41
▸ JAK2 O60674 1/20 0.41
▸ ABL1 P00519 1/20 0.41
▸ INSR P06213 1/20 0.41
▸ LYN P07948 1/20 0.41
▸ RET P07949 1/20 0.41
▸ IGF1R P08069 1/20 0.41
▸ MET P08581 1/20 0.41
▸ ROS1 P08922 1/20 0.41
▸ FGR P09769 1/20 0.41
▸ SRC P12931 1/20 0.41
▸ FLT1 P17948 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL396420 0.95 MAPK14 (0.45) FLT3FLT4KDRKITIDH2
SCHEMBL395533 0.94 FLT3 (0.48) FLT3FLT4KDRKITAURKB
SCHEMBL396423 0.93 FLT3 (0.51) FLT3FLT4KDRKITAURKB
SCHEMBL396893 0.93 FLT3 (0.47) FLT3FLT4KDRKITAURKB
SCHEMBL397179 0.92 NTRK1 (0.48) FLT3FLT4KDRKITAURKB
SCHEMBL398246 0.90 NTRK1 (0.53) FLT3FLT4KDRKITAURKB
SCHEMBL396166 0.89 TLK2 (0.47) NTRK1RETTLK2MAPK14AURKA
SCHEMBL394537 0.89 NTRK1 (0.52) FLT3FLT4KDRKITAURKB
SCHEMBL394110 0.87 FLT3 (0.48) FLT3FLT4KDRKITAURKB
SCHEMBL396154 0.86 MAPK14 (0.39) IDH2NTRK1TLK2MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 — — US claimed
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 — — US disclosed
Send feedback